Clinical Trials Browser

Neoplasms

NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Phase 2 Unknown

200 enrolled

Thoracic

Advanced NSCLC With EGFR Mutation

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Phase 2 Unknown

240 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00282100 2019-04-16

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Phase 2 Unknown

40 enrolled

Gastrointestinal

Liver Neoplasms

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2 Unknown

152 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT03486496 2018-04-03

Geber

Phase 2 Unknown

50 enrolled

Thoracic

Adenocarcinoma of Lung

NCT03399669 2018-01-16

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Phase 2 Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03123484 2017-04-21

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Phase 2 Unknown

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02951637 2016-11-01

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Phase 2 Unknown

300 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma

NCT02930954 2016-10-13

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase 2 Unknown

180 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02788058 2016-06-02

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Phase 2 Unknown

76 enrolled

Thoracic

Adenocarcinoma of Lung

NCT01955421 2015-07-03

NSCLC EGFR TKI

Phase 2 Unknown

224 enrolled

Thoracic

Advanced Stage Non Small Cell Lung Cancer

NCT02319577 2014-12-18

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Phase 2 Unknown

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01024712 2013-08-12

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Unknown

26 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01510990 2013-01-29

First Line Gefitinib by FDG-PET Metabolic Response

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01755923 2012-12-24

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01749072 2012-12-13

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Phase 2 Unknown

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01746277 2012-12-10

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01732276 2012-12-03

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Phase 2 Unknown

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01502202 2012-06-20

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Phase 2 Unknown

162 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01391260 2011-08-02

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01291823 2011-02-08

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Phase 2 Unknown

70 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01192243 2010-09-03

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Phase 2 Unknown

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00616499 2009-02-09

Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2 Unknown

35 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00614809 2008-02-22

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Phase 2 Unknown

45 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Clinical Trials

Efficacy and Safety of Precision Therapy in Refractory Tumor

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Geber

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NSCLC EGFR TKI

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

First Line Gefitinib by FDG-PET Metabolic Response

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer